Zydus Lifesciences completes acquisition of Sterling Biotech's API business
Zydus Lifesciences · Pharmaceuticals & Biotechnology
Key highlights
- Acquisition completed following conditions precedent and closing date adjustments.
- Business Transfer Agreement signed on September 17, 2024.
- Communication made to BSE Limited and National Stock Exchange of India on November 2, 2026.
Why it's rated notable: The filing confirms completion of the acquisition of Sterling Biotech's API business under the September 17, 2024 Business Transfer Agreement but states no consideration or value, so the level stays at medium.
Original filing
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Zydus Lifesciences
- Acquisition / mergerMajor development· Adverse for the businessZydus Lifesciences reports unaudited results for quarter ended September 30, 2026
Other acquisition / merger filings this fortnight
- Bansal Roofing Products Ltd approves Sept 2026 quarter results and DIPPL stake deal
- NDL Ventures Limited announces NCLT approval of merger with Hinduja Leyland Finance Ltd
- Vintage Coffee and Beverages: Q2 FY27 revenue ₹222.97 Cr; two subsidiaries merged
- S.J.S. Enterprises reports Q2 FY27 revenue up 16.9% YoY and H1 FY27 revenue up 20.4% YoY
- Nykaa reports Q2 FY2027 results; announces 82% stake acquisition in Simply Nam
- Varroc Q2 FY27 revenue up 33.6% YoY to ₹29,479 million; Italy restructuring planned
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.